Akademik Veri Yönetim Sistemi
Frontiers in Medicine, cilt.13, 2026 (SCI-Expanded, Scopus)
Background: The favorable experience with superselective transarterial chemoembolization (TACE) using lipiodol-bleomycin may lead some hepatopancreatobiliary surgery centers to offer it as first-line treatment for symptomatic/enlarging hemangiomas. Patients and methods: The charts of 56 patients treated at a university hospital between 2012 and 2018 were reviewed. The results were reported as median (range). Results: The indication was abdominal pain in 46 patients (concomitant enlargement in 12, enlargement and fever in 1), asymptomatic enlargement in 8 and possibility of adverse hemodynamic consequences in two. A single session was planned for 48 patients and two-sessions in 8; in addition, four patients required 2 (n: 2) or 3 (n: 2) sessions for symptom control. Six patients (11%), experienced post-embolization syndrome lasting longer than one week. Lesion volume decreased from 586 (147–8,435) cm3 to 332 (24–4,710) cm3 in 4 (2–8) months after the first session [p < 0.01; 46% (5–92) regression]. In the 8 patients who underwent two planned sessions, lesion volume decreased from 1,454 (441–8,435) cm3 to 661 (159–3,716) cm3, 5 (3–7) months after the second session [62% (37–78) regression]. Shrinkage in the 95%–99% range was observed in 13 (25%) of the 51 patients who were followed at least one year. Thirty-four (73%) of the 46 symptomatic patients reported resolution/marked amelioration of symptoms. No late complications were observed in 41 patients (73%) followed for at least 5 years; progressive regression was observed in 36 (88%) cases; in two patients (5%), initial regression was followed by regrowth. Conclusion: TACE is a successful first-line treatment for patients with symptomatic/enlarging hemangiomas. Better assessment of the quality of life in symptomatic patients and different definitions of success in cases with symptomatic and asymptomatic progressive enlargement are required.